Disclosed herein are ketamine derivatives that have been modified to reduce or prevent transference across the blood brain barrier. The ketamine derivatives will allow the reduction of pain in the patients without complications associated with psychotropic effects typically associated with unmodified ketamine.

The present disclosure provides human lipocalin muteins that bind CD137 and can be used in pharmaceutical applications, for example, as anti-cancer agents and/or immune modulators for the treatment or prevention of human diseases such as cancer, infectious diseases, and autoimmune diseases. The present disclosure also concerns methods of making CD137 binding lipocalin muteins described herein as well as compositions comprising such lipocalin muteins. The present disclosure further relates to nucleic acid molecules encoding such lipocalin muteins and to methods for generation of such lipocalin muteins and nucleic acid molecules. In addition, the application discloses therapeutic and/or diagnostic uses of these lipocalin muteins as well as compositions comprising one or more of such lipocalin muteins.

The present disclosure provides human lipocalin muteins that bind CD137 and can be used in pharmaceutical applications, for example, as anti-cancer agents and/or immune modulators for the treatment or prevention of human diseases such as cancer, infectious diseases, and autoimmune diseases. The present disclosure also concerns methods of making CD137 binding lipocalin muteins described herein as well as compositions comprising such lipocalin muteins. The present disclosure further relates to nucleic acid molecules encoding such lipocalin muteins and to methods for generation of such lipocalin muteins and nucleic acid molecules. In addition, the application discloses therapeutic and/or diagnostic uses of these lipocalin muteins as well as compositions comprising one or more of such lipocalin muteins.

Disclosed are immunogenic peptides of the HTT protein and HTT specific antibodies for use in the prevention and/or treatment of Huntington's disease.

The invention provides nanodroplets labeled with targeting ligands that are useful in the detection and treatment of vascular thromboses (e.g., fibrin clots) and vascular plaques, or related diseases and conditions, as well as methods of preparation and use thereof.

The invention provides nanodroplets labeled with targeting ligands that are useful in the detection and treatment of vascular thromboses (e.g., fibrin clots) and vascular plaques, or related diseases and conditions, as well as methods of preparation and use thereof.

The present invention relates to a method for determining the amount of an oligonucleotide present in a powdered form. The method does not require the experimental determination of the extinction coefficient of the oligonucleotide or the serial dilution and A260 measurement. The method is, for example, applicable to modified oligonucleotides including 2′ sugar-modified oligonucleotides, phosphorothioate oligonucleotides, reporter labelled oligonucleotides, and conjugated oligonucleotides.

The present invention relates to a method for determining the amount of an oligonucleotide present in a powdered form. The method does not require the experimental determination of the extinction coefficient of the oligonucleotide or the serial dilution and A260 measurement. The method is, for example, applicable to modified oligonucleotides including 2′ sugar-modified oligonucleotides, phosphorothioate oligonucleotides, reporter labelled oligonucleotides, and conjugated oligonucleotides.

The present invention provides a peptide of formula (I) or a pharmaceutical salt thereof wherein “m”, “n”, “p”, and “q” represent integers and are selected from 0 and 1; and “r” is comprised from 1 to 10; a linker birradical of formula (II), which is connecting an alpha carbon atom of an amino acid located at position “i” in the peptide sequence of formula (I) with an alpha carbon atom of an amino acid located at position “i+4” or “i+7” in the peptide sequence of formula (I); a C-terminal end corresponding to —C(O)R.sub.4; and a N-terminal end corresponding to —NHR.sub.5. Alternatively, the present invention provides a peptide or a pharmaceutical salt thereof which has an amino acid sequence with an identity from 85% to 95% with respect to sequence SEQ ID NO: 9: The peptides of the invention show anticancer activity. (I) TABLE-US-00001 (I) —[(Glu)m-(Lys)n-Ala-Ala-Lys-Val-Val-Ile-Leu-Lys- Lys-Ala-Thr-Glu-Tyr-Val-(His)p-(Ser)q].sub.r-

The present disclosure provides human lipocalin muteins that bind CD137 and can be used in pharmaceutical applications, for example, as anti-cancer agents and/or immune modulators for the treatment or prevention of human diseases such as cancer, infectious diseases, and autoimmune diseases. The present disclosure also concerns methods of making CD137 binding lipocalin muteins described herein as well as compositions comprising such lipocalin muteins. The present disclosure further relates to nucleic acid molecules encoding such lipocalin muteins and to methods for generation of such lipocalin muteins and nucleic acid molecules. In addition, the application discloses therapeutic and/or diagnostic uses of these lipocalin muteins as well as compositions comprising one or more of such lipocalin muteins.